Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Laparoscopia , Neoplasias Urológicas/cirurgia , Procedimentos Cirúrgicos Urológicos/métodos , Urologia/métodos , Ásia , Europa (Continente) , Laparoscopia/efeitos adversos , Seleção de Pacientes , Complicações Pós-Operatórias/etiologia , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , América do Sul , Fatores de Tempo , Resultado do Tratamento , Estados Unidos , Procedimentos Cirúrgicos Urológicos/efeitos adversosRESUMO
OBJECTIVE: We present our initial experience with the Perigee system for anterior vaginal wall prolapses repair. MATERIAL AND METHOD: 15 patients with anterior vaginal wall prolapse (mean age: 62 years old) underwent implanted with Perigee system which is composed by a mesh for correcting central defect and four self-attached horns for correcting lateral defect. The implanted procedure consist of four steps: 1) lateral vaginal wall dissection as far as isquiopubic branch; 2) performance of two upper marks at genitofemoral fold and two lower marks at 2 cm laterally and 3 cm lower; 3) insertion of the upper needles parallel to the isquiopubic branch and connection with the mesh's "arms" plus insertion of the lower needles vertically and connection with mesh's "legs"; 4) to adjust the mesh free tension. The system POP-Q was used as an objective measure of correction rate. RESULTS: Preoperatively, the point Aa was 0.09. After 6 weeks and three months postoperatively was -3.00 and -2.73 respectively. Preoperatively, the point Ba was 1.73. After 6 weeks and three months postoperatively was -2.82 and -2.82 respectively. No major complications were presented. No vascular damage or significant bleeding was observed. CONCLUSION: The transobturator correction of cystocele is an attractive alternative. The initial good outcome may be expected to be long lasting.
Assuntos
Doenças da Bexiga Urinária/cirurgia , Procedimentos Cirúrgicos Urológicos/métodos , Adulto , Idoso , Feminino , Procedimentos Cirúrgicos em Ginecologia/métodos , Humanos , Pessoa de Meia-Idade , Telas Cirúrgicas , Técnicas de Sutura , Resultado do Tratamento , Vagina/cirurgiaRESUMO
Six lactating women receiving long-term treatment with prednisolone in doses from 10 to 80 mg/day were studied. Serum and milk samples were assayed for prednisolone and endogenous cortisol by a specific high-performance liquid chromatographic method. The milk and serum concentrations vs time curves for prednisolone were virtually parallel, and the milk concentrations were 5% to 25% of those in serum. The milk/serum concentration ratio increased with increasing serum concentration. At a daily dose of 80 mg prednisolone, the infant would ingest less than 0.1% of that dose; this corresponds to less than 10% of the infant's endogenous cortisol production. Because there is an equilibrium between the concentration of prednisolone in milk and serum, the exposure of the infant is minimized if breast-feeding is avoided during the first 4 hours after the dose. We conclude that from a quantitative point of view the exposure of the infant is minimal, and breast-feeding may be permitted at maternal prednisolone doses of at least 20 mg once or twice daily. At higher doses, exposure may be minimized if nursing is performed greater than 4 hours after the dose.
Assuntos
Leite Humano/metabolismo , Prednisolona/metabolismo , Feminino , Humanos , Cinética , Prednisolona/sangue , Fatores de TempoAssuntos
Anormalidades Induzidas por Medicamentos/etiologia , Lítio/efeitos adversos , Anormalidades Múltiplas/induzido quimicamente , Transtorno Bipolar/tratamento farmacológico , Feminino , Cardiopatias Congênitas/induzido quimicamente , Humanos , Recém-Nascido , Troca Materno-Fetal , Gravidez , Complicações na Gravidez/tratamento farmacológicoRESUMO
The plasma half-life of diphenylhydantoin newborn infants of epileptic mothers, treated with this drug, is in the same range as the plasma half-life in adults. The urinary excretion of diphenylydantoin and its main metabolites has been investigated in six newborn infants. The results show that the rapid plasma disappearance of diphenylhydantoin is due to rapid metabolism of the drug.